Rapid Micro Biosystems (RPID) said Tuesday it expects Q4 revenue of about $8.2 million, up about 30% from a year earlier.
Two analysts polled by FactSet expect $7.6 million.
The company expects full-year 2024 revenue of about $28.1 million, up about 25% from a year earlier.
Two analysts surveyed by FactSet expect $27.5 million.
Rapid also said it is launching a collaboration with Lonza to integrate Rapid's Growth Direct systems and Lonza's MODA-EM module to create an environmental monitoring quality control product.
Lonza will deploy the solution across its cell and gene therapy manufacturing network, according to Rapid.
Rapid shares were rising nearly 15% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.